7/102 sources · 2 publishersUpdated Nov 4, 08:24 UTC
Ultragenyx reaffirms 2027 profitability goal after cutting GTX‑102 and cutting workforce
Ultragenyx Pharmaceutical announced it will pursue GAAP profitability by 2027, targeting R&D spending below $350 million and SG&A below $375 million. The company discontinued its GTX‑102 program, ended two clinical studies and will reduce its workforce by about 20%. It also reported FDA approval of two drugs and reiterated its 2027 profit target.
Why it matters
The cost‑reduction plan and profit target could improve margins and support higher valuations, as reflected by an average 12‑month price target of $26.40 from analysts. The workforce cut and program shutdown may affect short‑term execution risk.
Key facts
- 1Ultragenyx aims for GAAP profitability by 2027. seekingalpha.com
- 2The company plans R&D expenses under $350 million. seekingalpha.com
- 3The company plans SG&A expenses under $375 million. seekingalpha.com
- 4Ultragenyx discontinued its GTX‑102 program. seekingalpha.com
- 5Ultragenyx ended two clinical studies. tradingview.com
- 6The firm announced a roughly 20% reduction in its workforce. tradingview.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.